Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Catalyst Pharm Inc
(NQ:
CPRX
)
21.46
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Catalyst Pharm Inc
< Previous
1
2
3
4
5
6
7
Next >
Amphastar Casts Wide Net, Hauls In Profits, Gets Rating Upgrade
October 15, 2024
Amphastar hit an all-time high in August 2023 and consolidated. It could be forming the right side of a cup base that started in January.
Via
Investor's Business Daily
NASDAQ:CPRX—Positioned as a High-Growth Stock, Ready for a Potential Breakout.
October 14, 2024
Exploring the Growth Potential of CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) as It Nears a Breakout.
Via
Chartmill
Alkermes Stock Jumps Nearly 30% In 3 Months Amid Hefty Profits
October 14, 2024
Alkermes develops treatments for neurodegenerative diseases (conditions that damage and destroy parts of the nervous system) and cancer.
Via
Investor's Business Daily
Looking for growth without the hefty price tag? Consider NASDAQ:CPRX.
October 09, 2024
While growth is established for CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX), the stock's valuation remains reasonable.
Via
Chartmill
A Biotech Breakout Will Be Led By Small Caps
September 23, 2024
It’s hard to focus on biotech stocks right now because there are many distractions. The Fed and the rate cuts, AI and semiconductor stocks and geopolitical turmoil seemingly worse than ever.
Via
Talk Markets
Topics
Artificial Intelligence
Economy
Exposures
Artificial Intelligence
Interest Rates
Why NASDAQ:CPRX Is a Standout High-Growth Stock in a Consolidation Phase.
September 19, 2024
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX): a strong growth stock preparing for the next leg up?.
Via
Chartmill
NASDAQ:CPRX is showing good growth, while it is not too expensive.
September 13, 2024
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is not too expensive for the growth it is showing.
Via
Chartmill
Exploring the Growth Potential of NASDAQ:CPRX as It Nears a Breakout.
August 29, 2024
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) qualifies as a high growth stock and is consolidating.
Via
Chartmill
The Latest Analyst Ratings For Catalyst Pharmaceuticals
August 12, 2024
Via
Benzinga
Keros Therapeutics Stock Meets 80-Plus RS Rating Benchmark
September 05, 2024
Building your watch list, look for stocks with an 80-plus RS Rating. Keros Therapeutics stock just met that criteria with a new score of 86.
Via
Investor's Business Daily
Innovative Drugmaker Roivant Puts Up Really Healthy Sales Numbers
August 29, 2024
Roivant stock has an outstanding A- Accumulation/Distribution Rating, showing that institutions such as mutual funds are fairly heavy buyers.
Via
Investor's Business Daily
Biohaven Stock Earns Relative Strength Rating Upgrade
August 21, 2024
Biohaven stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 88 to 91.
Via
Investor's Business Daily
SpringWorks Therapeutics Stock Clears Key Benchmark, Hitting 80-Plus RS Rating
August 21, 2024
A Relative Strength Rating upgrade for SpringWorks Therapeutics shows improving technical performance.
Via
Investor's Business Daily
Investors should take notice of NASDAQ:CPRX—it offers a great deal for the fundamentals it presents.
August 21, 2024
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX), an undervalued stock with good fundamentals.
Via
Chartmill
NASDAQ:CPRX stands out as a growth opportunity that won't break the bank.
August 21, 2024
Don't overlook CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX)—a stock with solid growth prospects and a reasonable valuation.
Via
Chartmill
A Closer Look at 7 Analyst Recommendations For Catalyst Pharmaceuticals
June 03, 2024
Via
Benzinga
Decoding 8 Analyst Evaluations For Catalyst Pharmaceuticals
May 10, 2024
Via
Benzinga
Decoding 7 Analyst Evaluations For Catalyst Pharmaceuticals
March 27, 2024
Via
Benzinga
Immunome Stock Sees RS Rating Jump To 91
August 20, 2024
Immunome stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 88 to 91.
Via
Investor's Business Daily
PTC Therapeutics Stock Earns RS Rating Upgrade To 83
August 19, 2024
The Relative Strength (RS) Rating for PTC Therapeutics stock climbed into a new percentile Monday, with a rise from 80 to 83.
Via
Investor's Business Daily
Top 3 Health Care Stocks That May Crash In August
August 14, 2024
Via
Benzinga
CPRX Stock Earnings: Catalyst Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
August 07, 2024
CPRX stock results show that Catalyst Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Top 3 Health Care Stocks You May Want To Dump This Quarter
July 30, 2024
Via
Benzinga
Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark
July 26, 2024
On Friday, Vir Biotechnology stock had its Relative Strength (RS) Rating upgraded to 82, up from 64 a day earlier.
Via
Investor's Business Daily
Trading SMID Biotech Stocks In A Volatile Market
July 01, 2024
Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a...
Via
Talk Markets
2 Incredible Growth Stocks to Buy Hand Over Fist Right Now
May 15, 2024
These two healthcare stocks may be deeply undervalued.
Via
The Motley Fool
Catalyst Pharmaceuticals Stock Clears Technical Benchmark With 83 RS Rating
May 14, 2024
On Tuesday, Catalyst Pharmaceuticals stock hit a key technical milestone, with its Relative Strength Rating climbing to 83 from 79.
Via
Investor's Business Daily
Catalyst's New CEO Has Big Ideas For The Small Biotech
May 10, 2024
Richard Daly is Catalyst Pharmaceuticals' second CEO, taking over for Patrick McEnany, who retired last year.
Via
Investor's Business Daily
CPRX Stock Earnings: Catalyst Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
May 08, 2024
CPRX stock results show that Catalyst Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Top 10% Biotech Catalyst Pharma Slips On Mixed First-Quarter
May 08, 2024
The company doubled Wall Street's earnings views, but sales came in short.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.